Drug intelligence / Profile preview

inactivated EV71 vaccine

Development stage
Phase 4
Lead developer
Sinovac Biotech
Modality
Vaccines & Immunotherapeutics
Administration
Intramuscular
01

Overview

The inactivated EV71 vaccine is a prophylactic pharmaceutical agent designed to prevent Hand, Foot, and Mouth Disease (HFMD) caused by Enterovirus 71 (EV71), a significant public health concern primarily in the Asia-Pacific region. This vaccine utilizes inactivated, whole EV71 virus particles, often formulated with an adjuvant like aluminum hydroxide, to stimulate the body's immune system. Upon administration, the vaccine induces the production of specific neutralizing antibodies and T-cell responses against EV71, thereby providing immunity without causing the disease. Multiple organizations, predominantly in China, have developed and brought these vaccines to market, demonstrating high efficacy and safety in clinical trials, particularly in young children.

Brand names
Inlive
Other names
Enterovirus 71 vaccine (inactivated)EV71vacEV-71vacEV 71vac
02

Targets

Enterovirus 71 capsid protein VP2VP1 pocket (VP1 capsid hydrophobic pocket)VP3 (Enterovirus 71 capsid protein VP3)

Beyond the preview

Go deeper on inactivated EV71 vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on inactivated EV71 vaccine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call